Clinical Trial Update: A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19 [Phase 2]

View source ↗

Summary

Phase 2 study evaluating axatilimab for hospitalized COVID-19 patients with respiratory involvement was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus
• Respiratory Distress Syndrome

Drugs mentioned

• Axatilimab (axatilimab)

Snippet

Sponsor: Syndax Pharmaceuticals | Conditions: Coronavirus, COVID | Phase 2 | Status: TERMINATED | Results posted: 2022-07-22